Shield Therapeutics
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	12/31/2021	12/31/2022	12/31/2023	12/31/2025	12/31/2026	12/31/2027
Revenue % change YoY	£1.51M N/A	£4.46M 194.07%	£13.08M 192.92%	Avg: £89.29M Low: £61.80M High: £116.77M avg. 582.39%	Avg: £64.46M Low: £46.53M High: £82.29M avg. -27.80%	Avg: £89.12M Low: £64.33M High: £113.77M avg. 38.25%
Net Income % change YoY	£-19.33M N/A	£-40.44M -109.16%	£-33.29M 17.68%	Avg: £4.36M Low: £-5.76M High: £13.75M avg. 113.10%	Avg: £-6.48M Low: £-8.82M High: £-4.14M avg. -248.73%	Avg: £2.53M Low: £1.62M High: £3.45M avg. 139.13%
EBITDA % change YoY	£-17.35M N/A	£-22.62M -30.39%	£-30.28M -33.88%	Avg: £-70.02M Low: £-91.58M High: £-48.46M avg. -131.19%	Avg: £-50.55M Low: £-64.53M High: £-36.49M avg. 27.80%	Avg: £-69.89M Low: £-89.22M High: £-50.45M avg. -38.25%
EPS % change YoY	-$0.09 N/A	-$0.17 -79.70%	-$0.04 78.17%	Avg: $0.01 Low: -$0.01 High: $0.02 avg. 114.91%	Avg: -$0.01 Low: -$0.01 High: -$0.01 avg. -262.24%	Avg: $0 Low: $0 High: $0 avg. 139.13%
Operating Expenses % change YoY	£20.49M N/A	£27.70M 35.19%	£35.35M 27.63%	Avg: £508.28M Low: £351.81M High: £664.75M avg. 1337.53%	Avg: £366.94M Low: £264.91M High: £468.45M avg. -27.80%	Avg: £507.31M Low: £366.25M High: £647.65M avg. 38.25%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of 1.16% in 2025-2027.

We have gathered data from 2 analysts. Their low estimate is -5.76M, average is 4.36M and high is 13.75M.

Wall Street analysts forecast annual average revenue growth of 197.61% in 2025-2027.

We have gathered data from 2 analysts. Their low revenue estimate is £61.80M, average is £89.29M and high is £116.77M.

Wall Street analysts forecast annual average earnings growth of -2.73% in 2025-2027.

We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.01, average is $0.01 and high is £0.01.